Optic IconOptic Logo
|
SearchCollectionsBenchmarks
Organization

Exactis Innovation

2 abstracts

Abstract
Circulating tumor DNA detection after neoadjuvant chemotherapy and prediction of distant relapse free survival, local recurrence, and distant recurrence in triple-negative breast cancer in the TRICIA study.
Org: Lady Davis Institute of the Jewish General Hospital, Jewish General Hospital Stroll Cancer Prevention Centre, Montreal, QC, Canada, Canada, Jewish General Hospital-Sir Mortimer B. Davis Jewish General Hospital,
Abstract
Exactis-03: A phase I trial of the combination of olaparib and navitoclax in women with high grade serous ovarian cancer and triple negative breast cancer.
Org: Odette Cancer Centre, Sunnybrook Health Sciences Centre, University of Montreal, Centre De Recherche Du Centre Hospitalier De L'université De Montréal (CRCHUM), Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy,